In this free webinar, learn why antibody-drug conjugate (ADC) programs benefit from a "fail faster" approach to reduce late-stage attrition and accelerate development. Attendees will gain insight into ...

The antibody-drug conjugate (ADC) manufacturing landscape offers the potential to leverage significant opportunities for cancer treatment, but faces complex challenges. Nevertheless, the ADC market ...

The interest in the potential of antibody-drug conjugates (ADC) continues to grow among some of pharma’s biggest players. Bristol Myers Squibb (BMS) announced Thursday morning that it has entered into ...

(RTTNews) - WuXi XDC, a global leading Contract Research, Development and Manufacturing Organization dedicated to end-to-end bioconjugates services, and AbTis, a Korean biotechnology company dedicated ...

SUZHOU, China, Nov. 13, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that a clinical trial (Study ID: JSKN033-102) of JSKN033, a high-concentration subcutaneous ...

SUZHOU, China, Dec. 26, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that a phase I/II clinical trial (Study ID: JSKN033-102) of JSKN033, a high-concentration subcutaneous co ...

Alphamab Oncology (Stock Code: 9966.HK) announced that the IND application for a Phase II clinical study of JSKN033 (a ...

Mycenax Biotech Inc., a leading biologics CDMO based in Taiwan, announced strategic alliance with Spera Pharma Inc., a Japan-based expert in pharmaceutical chemistry, manufacturing, and controls (CMC) ...

SAN DIEGO – December 10 th, 2015 — Ajinomoto Althea, Inc. ("Althea"), a leading provider of biopharmaceutical contract development and manufacturing services, recently announced it is expanding its ...

TAIPEI, Sept. 15, 2025 /PRNewswire/ -- Mycenax Biotech Inc. (TWO:4726), a leading biologics CDMO based in Taiwan, today announced strategic alliance with SPERA PHARMA Inc., a Japan-based expert in ...